Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.58 |
| ▸ | AXL | P30530 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 8/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.37 |
| ▸ | CDK9 | P50750 | 6/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.36 |
| ▸ | CDK1 | P06493 | 6/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21403 | 0.85 | SYK (0.42) | SYKEIF2AK4CDK1KDR | |
| SCHEMBL15221173 | 0.83 | SYK (0.60) | SYKEIF2AK4AXLCDK2CCNA2 | |
| SCHEMBL15210473 | 0.82 | SYK (0.59) | SYKEIF2AK4AXLCDK2CCNA2 | |
| SCHEMBL15207760 | 0.81 | SYK (0.56) | SYKEIF2AK4CDK2CCNA2TTK | |
| SCHEMBL15212574 | 0.81 | SYK (0.58) | SYKEIF2AK4CDK2CCNA2TTK | |
| SCHEMBL15210682 | 0.81 | JAK3 (0.50) | TTK | |
| SCHEMBL19982799 | 0.81 | SYK (0.41) | SYKEIF2AK4 | |
| SCHEMBL15210918 | 0.80 | SYK (0.53) | SYKEIF2AK4AXLCDK2CCNA2 | |
| SCHEMBL15210467 | 0.80 | SYK (0.58) | SYKEIF2AK4CDK2CCNA2TTK | |
| SCHEMBL15212567 | 0.80 | SYK (0.58) | SYKEIF2AK4AXLCDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | claimed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | SYK 1/4885EIF2AK4 1898/4885AXL 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.